https://www.aigom.it/wp-content/uploads/2025/03/IMM18.3.png1136960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-03-18 08:35:452025-03-18 08:35:45OSIMERTINIB AFTER CHEMORADIOTHERAPY IN STAGE III EGFR-MUTATED NSCLC.
https://www.aigom.it/wp-content/uploads/2025/03/LOC.11.3.png1342960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-03-11 08:47:002025-03-11 08:47:00FIRST-LINE NIVOLUMAB PLUS RELATLIMAB VERSUS NIVOLUMAB PLUS IPILIMUMAB IN ADVANCED MELANOMA: AN INDIRECT TREATMENT COMPARISON USING RELATIVITY-047 AND CHECKMATE 067 TRIAL DATA.
https://www.aigom.it/wp-content/uploads/2025/03/loc14-15-3.png706748Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-03-04 09:23:052025-03-17 08:45:32NEGRAR DI VALPOLICELLA (VE)-SCUOLA DI METODOLOGIA DELLA RICERCA CLINICA 2025-11° EDIZIONE VENERDI 14-SABATO 15 MARZO 2025
https://www.aigom.it/wp-content/uploads/2025/03/art4.3.png1242960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-03-04 08:49:132025-03-04 08:58:47FINAL, 10-YEAR OUTCOMES WITH NIVOLUMAB PLUS IPILIMUMAB IN ADVANCED MELANOMA.
https://www.aigom.it/wp-content/uploads/2025/02/Screenshot-2025-02-27-094112.png680749Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-02-27 09:07:102025-03-04 09:27:03SCUOLA DI METODOLOGIA DELLA RICERCA CLINICA 2025-11° EDIZIONE VENERDI 14-SABATO 15 FEBBRAIO 2025
https://www.aigom.it/wp-content/uploads/2025/02/25.02.png1353960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-02-25 08:25:392025-02-25 08:25:39BREAST CANCER BRAIN METASTASIS: A COMPREHENSIVE REVIEW.
https://www.aigom.it/wp-content/uploads/2025/02/ART18.2.png1201960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-02-18 08:50:152025-02-18 08:50:15SURVIVAL WITH CEMIPLIMAB IN RECURRENT CERVICAL CANCER.
https://www.aigom.it/wp-content/uploads/2025/02/ART11.2.png1471960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-02-11 08:40:452025-02-11 08:40:45DAROLUTAMIDE IN COMBINATION WITH ANDROGEN-DEPRIVATION THERAPY IN PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER FROM THE PHASE III ARANOTE TRIAL.
